DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,074 filers reported holding DANAHER CORPORATION in Q4 2022. The put-call ratio across all filers is 1.10 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $16,961,109 | +4.0% | 68,364 | +0.6% | 0.90% | 0.0% |
| Q2 2023 | $16,314,720 | -3.6% | 67,978 | +1.2% | 0.90% | -10.3% |
| Q1 2023 | $16,926,503 | -4.5% | 67,158 | +0.5% | 1.00% | -7.3% |
| Q4 2022 | $17,733,241 | +4.2% | 66,812 | +1.4% | 1.08% | -8.2% |
| Q3 2022 | $17,018,000 | +1.7% | 65,887 | -0.2% | 1.17% | +5.6% |
| Q2 2022 | $16,738,000 | -12.6% | 66,023 | +1.1% | 1.11% | -0.4% |
| Q1 2022 | $19,160,000 | -4.4% | 65,319 | -0.8% | 1.12% | -13.1% |
| Q4 2021 | $20,045,000 | 0.0% | 65,841 | 0.0% | 1.28% | 0.0% |
| Q3 2021 | $20,045,000 | +12.4% | 65,841 | -0.9% | 1.28% | +12.8% |
| Q2 2021 | $17,833,000 | +18.4% | 66,450 | -0.7% | 1.14% | +12.3% |
| Q1 2021 | $15,058,000 | +1.3% | 66,902 | -0.0% | 1.01% | -22.0% |
| Q4 2020 | $14,865,000 | -0.3% | 66,919 | -3.3% | 1.30% | -14.9% |
| Q3 2020 | $14,907,000 | +18.9% | 69,229 | -2.4% | 1.53% | +9.5% |
| Q2 2020 | $12,539,000 | +30.6% | 70,910 | +2.3% | 1.40% | +8.2% |
| Q1 2020 | $9,598,000 | -9.7% | 69,346 | +0.2% | 1.29% | +8.4% |
| Q4 2019 | $10,627,000 | +6.1% | 69,238 | -0.1% | 1.19% | -2.3% |
| Q3 2019 | $10,015,000 | +0.3% | 69,342 | -0.8% | 1.22% | -1.1% |
| Q2 2019 | $9,989,000 | +8.8% | 69,892 | +0.5% | 1.23% | +3.3% |
| Q1 2019 | $9,178,000 | +29.9% | 69,517 | +1.5% | 1.19% | +12.2% |
| Q4 2018 | $7,063,000 | -2.7% | 68,497 | +2.5% | 1.06% | +8.9% |
| Q3 2018 | $7,258,000 | +11.5% | 66,796 | +1.3% | 0.98% | +5.0% |
| Q2 2018 | $6,509,000 | +3.7% | 65,961 | +2.9% | 0.93% | +1.2% |
| Q1 2018 | $6,276,000 | +8.2% | 64,096 | +2.6% | 0.92% | +10.2% |
| Q4 2017 | $5,800,000 | +11.6% | 62,481 | +3.1% | 0.83% | +4.5% |
| Q3 2017 | $5,199,000 | +2.4% | 60,604 | +0.7% | 0.80% | -0.5% |
| Q2 2017 | $5,077,000 | +0.7% | 60,160 | +2.1% | 0.80% | -0.9% |
| Q1 2017 | $5,040,000 | +11.4% | 58,928 | +1.4% | 0.81% | +8.3% |
| Q4 2016 | $4,523,000 | +4.4% | 58,100 | +5.1% | 0.75% | -3.6% |
| Q3 2016 | $4,332,000 | -19.0% | 55,265 | +4.3% | 0.77% | -19.7% |
| Q2 2016 | $5,349,000 | +16.9% | 52,965 | +9.8% | 0.96% | +9.7% |
| Q1 2016 | $4,574,000 | +2.8% | 48,221 | +0.6% | 0.88% | -7.9% |
| Q4 2015 | $4,450,000 | +13.5% | 47,911 | +4.1% | 0.95% | +1.7% |
| Q3 2015 | $3,921,000 | +2.5% | 46,014 | +3.0% | 0.94% | +7.2% |
| Q2 2015 | $3,825,000 | +1.1% | 44,684 | +0.2% | 0.88% | +0.3% |
| Q1 2015 | $3,785,000 | +3.2% | 44,582 | +4.2% | 0.87% | -2.0% |
| Q4 2014 | $3,669,000 | +10.7% | 42,804 | -1.9% | 0.89% | +6.3% |
| Q3 2014 | $3,315,000 | -5.5% | 43,624 | -2.1% | 0.84% | -0.5% |
| Q2 2014 | $3,509,000 | +4.6% | 44,564 | -0.4% | 0.84% | +2.6% |
| Q1 2014 | $3,355,000 | -3.4% | 44,738 | -0.5% | 0.82% | -2.6% |
| Q4 2013 | $3,472,000 | +10.7% | 44,973 | -0.6% | 0.84% | +3.2% |
| Q3 2013 | $3,135,000 | +10.6% | 45,228 | +1.0% | 0.82% | +5.0% |
| Q2 2013 | $2,835,000 | – | 44,793 | – | 0.78% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |